Research Paper Volume 12, Issue 24 pp 25189—25206

Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma

class="figure-viewer-img"

Figure 1. SETD2 is clinically relevant in human LUAD. (A) Box plot of SETD2 expression levels in patients with lung cancer from TCGA. (B) The association of SETD2 expression at the mRNA level and overall survival using TCGA data (P values by log-rank test). (C) Scatter plot of SETD2 expression levels in LUAD tumors and adjacent normal epithelial tissues. (D) Real-time qPCR analysis of SETD2 expression in HBE cells and human lung cancer cell lines A549, H1975, H1299, H1650 and PC-9. (E) Western blotting analyses of SETD2 expression at the protein level in four clinical stages of lung cancer progression using human lung tissue specimens. (F) SETD2 staining of human lung cancer tissues with four clinical stages of cancer progression. Scale bars: 50 μm. *P<0.05, **P<0.01. Two-tailed Student’s t test.